Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer
Journal
Future Oncology
Journal Volume
17
Journal Issue
8
Pages
965-977
Date Issued
2021
Author(s)
Abstract
While randomized controlled trials (RCTs) are the gold standard for evidence-based medicine, they do not always reflect real-world patient populations, limiting their generalizability and external validity. Real-world evidence (RWE), generated during routine clinical practice, is increasingly important in determining effectiveness outside of the tightly controlled conditions of RCTs, and is now recognized by regulatory bodies as a valuable complement to RCTs. Consequently, it is increasingly important for physicians to understand how RWE data can be used alongside clinical trial data. Here, we discuss the different types of real-world observational studies, outline the benefits and limitations of RWE, and, using examples from EGFR mutation-positive non-small-cell lung cancer, outline how RWE can be used to help inform treatment decisions. ? 2021 Future Medicine Ltd.. All rights reserved.
Subjects
EGFR mutation-positive; EGFR TKIs; NSCLC; real-world
SDGs
Other Subjects
afatinib; dacomitinib; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; osimertinib; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; acne; decision making; diarrhea; drug safety; dry skin; EGFR gene; evidence based medicine; gene; gene mutation; human; non small cell lung cancer; practice guideline; priority journal; rash; Review; adjuvant chemotherapy; electronic health record; gain of function mutation; genetics; lung resection; lung tumor; mortality; non small cell lung cancer; oncology; personalized medicine; procedures; randomized controlled trial (topic); statistical analysis; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Electronic Health Records; ErbB Receptors; Evidence-Based Medicine; Gain of Function Mutation; Humans; Lung Neoplasms; Medical Oncology; Pneumonectomy; Precision Medicine; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic
Publisher
Future Medicine Ltd.
Type
review